Inverness Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Inverness Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-142,804	Closed	-$26.2M	–	124
2019 Q2	$26.2M	Sell	142,804 -63,502	-31%	-$11.1M	1.34%	31
2019 Q1	$38M	Buy	206,306 +92,891	+82%	+$17.2M	2.07%	14
2018 Q4	$18.8M	Sell	113,415 -38,436	-25%	-$6.66M	1.26%	29
2018 Q3	$29.3M	Buy	151,851 +33,331	+28%	+$5.94M	1.54%	28
2018 Q2	$20.1M	Buy	118,520 +38,050	+47%	+$5.9M	1.15%	32
2018 Q1	$13.1M	Buy	+80,470	New	+$13.1M	0.79%	39

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Inverness Counsel's VRTX Position: Q3 2019 in Review

Inverness Counsel sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 142,804 shares — an estimated $26.2M sold.

Inverness Counsel first reported a position in VRTX in Q1 2018 and held it in 6 quarters. The position peaked at $38M in Q1 2019. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Inverness Counsel reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Inverness Counsel sold 142,804 Vertex Pharmaceuticals shares in Q3 2019, an estimated $26.2M.
Inverness Counsel first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Inverness Counsel's Vertex Pharmaceuticals position peaked at $38M in Q1 2019.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Inverness Counsel's 13F filing for Q3 2019, filed 12 Nov 2019.